Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2

Karan Pattni, Daniel Hungerford, Sarah Adams, Iain Buchan, Christopher P Cheyne, Marta García-Fiñana, Ian Hall, David M Hughes, Christopher Overton, Xingna Zhang, Kieran J. Sharkey
doi: https://doi.org/10.1101/2021.10.12.21264840
Back to top
Posted October 14, 2021.
Download PDF

Supplementary Material

Data/Code
Email
Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2
Karan Pattni, Daniel Hungerford, Sarah Adams, Iain Buchan, Christopher P Cheyne, Marta García-Fiñana, Ian Hall, David M Hughes, Christopher Overton, Xingna Zhang, Kieran J. Sharkey
medRxiv 2021.10.12.21264840; doi: https://doi.org/10.1101/2021.10.12.21264840
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area